Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.
U.S. FDA grants Breakthrough Therapy Designation for Roche’s investigational medicine ocrelizumab in primary progressive multiple sclerosis
Unusual association of Arnold-Chiari malformation and vitamin B12 deficiency.
A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis.
New therapies in the management of rheumatoid arthritis.
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
Multiple sclerosis and pregnancy: experience from a nationwide database in Germany.
A Study of Efficacy and Safety of Ocrelizumab in Patients with Relapse-Remitting Multiple Sclerosis
Safety study of BIIB033 in subjects with multiple sclerosis
Efficacy and Safety of GTR in Comparison to Copaxone® (GATE)
Histologie de la sclerose en plaques
Efficacy and safety of BG-12 (dimethyl fumarate) and other disease modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice.
Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial.
Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists.
Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis Optica: Multicenter Study of Treatment Efficacy.
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
Development of oral immunomodulatory agents in the management of multiple sclerosis.
Ocrelizumab Bests Interferon in Relapsing-Remitting MS
Protective effect of breastfeeding in postpartum relapse rate of mothers with multiple sclerosis.
Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis.
Immunomodulatory agents and risk of postpartum multiple sclerosis relapses.
LINGO-1 negatively regulates myelination by oligodendrocytes.
Epitope spreading as an early pathogenic event in pediatric multiple sclerosis.
Breast-feeding, postpartum and prepregnancy disease activity in multiple sclerosis.

Pages